Page 1

verve THERAPEUTICS Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results November 10 , 2021 VERVE - 101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent , Durable PCSK9 Protein and LDL - C Reductions , Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3 Program Highlight Potent Editing with Proprietary GalNAc - LNP Delivery in a Novel NHP Model of Homozygous Familial Hypercholesterolemia Ended Third Quarter of 2021 with $ 389.2 million in Capital CAMBRIDGE , Mass . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Verve Therapeutics , Inc. , ( Nasdaq : VERV ) , a biotech company pioneering a new approach to the care of cardiovascular disease with single - course gene editing medicines , today reported pipeline and business highlights and third quarter 2021 financial results . " We're thrilled with the progress we've made thus far in 2021 , exemplified by recent preclinical data readouts from our lead programs targeting PCSK9 and ANGPTL3 , " said Sekar Kathiresan , M.D. , co - founder and chief executive officer of Verve . “ Data from our VERVE - 101 program targeting PCSK9 demonstrate its potential to safely and durably lower disease - causing high LDL - C , a key driver of atherosclerotic cardiovascular disease , and support our plans to initiate clinical development in 2022. Preclinical data from our ANGPTL3 program , including exciting data highlighting our proprietary GalNAc - LNP delivery technology , could allow us to reach even more patients with our single - course gene editing medicines . Backed by an expert team and a strong balance sheet , we stand well positioned to advance our gene editing therapies and fundamentally change the way cardiovascular disease is treated . " Pipeline Highlights • VERVE - 101 Clinical Initiation on Track for 2022. Data presented during an oral session at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference ( TIDES 2021 ) demonstrated that administration of VERVE - 101 , Verve's lead gene editing therapy targeting PCSK9 , led to potent and durable lowering of both blood PCSK9 protein and disease - causing low - density lipoprotein cholesterol ( LDL - C ) , with no evidence of adverse events or significant off - target , bystander or germline editing , in non - human primates ( NHPs ) . Based on these data , Verve plans to pursue regulatory submissions and begin clinical development of VERVE - 101 in 2022 , initially focused on patients with heterozygous familial hypercholesterolemia ( HeFH ) , a prevalent form of atherosclerotic cardiovascular disease ( ASCVD ) . • Preclinical Data Highlight Liver - Targeted Delivery with Proprietary GalNAc - LNP Technology . Verve recently announced preclinical data highlighting the development of a potent , in vivo liver - targeting lipid nanoparticle ( LNP ) delivery technology using a novel GalNAc - targeting ligand . Findings show that Verve's ANGPTL3 - targeted base editor , delivered via its GalNAc - LNP , was taken up in the livers of NHPs , reduced blood ANGPTL3 protein by 94-97 % and lowered LDL - C in an internally developed NHP model of homozygous familial hypercholesterolemia ( HoFH ) , a rare form of ASCVD . These findings build upon in vivo data presented at TIDES 2021 showing that the company's proprietary GalNAc - LNP achieved high efficiency liver delivery and base editing in mouse models of HoFH . Verve is advancing development of its GalNAc - LNP technology and plans to select the development candidate for its ANGPTL3 program in 2022 . Upcoming Investor Conference Presentation • Jefferies 2021 Virtual London Healthcare Conference . Dr. Kathiresan and Andrew Bellinger , M.D. , Ph.D. , chief scientific officer and chief medical officer , will participate in a fireside chat during the Jefferies 2021 Virtual London Healthcare Conference , being held November 16-19 , 2021. The fireside chat will be available to registered participants on - demand between 8:00 a.m. GMT on November 18 , 2021 , and 5:00 p.m. GMT on November 19 , 2021. The webcast will be available in the investor section of the company's website at www.vervetx.com , and will be archived for 60 days following the presentation . Third Quarter 2021 Financial Results • Cash Position : Cash , cash equivalents and marketable securities were $ 389.2 million as of September 30 , 2021 , as compared to $ 72.1 million as of December 31 , 2020 . • Research & Development ( R & D ) Expenses : R & D expenses were $ 17.5 million for the third quarter of 2021 , as compared to $ 7.6 million for the third quarter of 2020. This increase was primarily due to additional investment in preclinical studies and manufacturing activities to support future clinical trials , and higher personnel costs ( including noncash stock - based